Frazier Healthcare Partners — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Co-investorsLongitude Capital
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDamien McDevitt(President and Chief Executive Officer)in
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+4 more
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsHighlight CapitalAmgen VenturesBlackRockBlackstone Life SciencesClarus VenturesGreenspring Associates+4 more
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.
BiotechHealthtechCarmel, US
Richard DiMarchi(Executive Officer, Director)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSteve Hoerter(Chairman & Chief Executive Officer)inSalomon Azoulay(Chief Medical Officer)inKaren Basbaum(Chief Business Officer)in
Co-investorsFrazier Life SciencesNorwest Venture PartnersIU VenturesNew Enterprise Associates (NEA)OrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.